SecBot SecBot
6-K ·Filed Oct 26, 2026

IMTX

Immatics N.V.
BULLISH
Impact 5/10
Processed1h 36m ago SEC0000950103-26-016136
Notable filing: 6-K

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0000950103-26-016136
Document: dp255472_ex9902.htm0000950103-26-016136
Document: dp255472_ex9901.htm0000950103-26-016136
Document: dp255472_6k.htm0000950103-26-016136
Document: dp255472_ex9903.htm0000950103-26-016136
Document: 0000950103-26-016136-index-headers.html0000950103-26-016136
Document: 0000950103-26-016136-index.html0000950103-26-016136
Document: 0000950103-26-016136.txt0000950103-26-016136
19 reports for IMTX
Performance horizon
55% Hit rate @ T+5 6 of 11 directional calls Went positive at some point 7 of 11 best @ T+20▲ +22.12%May 12, 2026
Filters
Rows
Reports for IMTX — sortable, filterable
TypeNow
Oct 26, 2026
today
6-K
BULLISH ★ 5/10
—awaiting T+5——
Oct 24, 2026
2d ago
Press Release
BULLISH ★ 6/10
$7.31awaiting T+5—$7.31 (−0.00%)
Oct 23, 2026
3d ago
6-K
BULLISH ★ 7/10
$7.60awaiting T+5—$7.31 (−3.82%)
Aug 27, 2026
8w ago
Insider Buy
BULLISH ★ 6/10
$9.45 $9.56▲ +1.16%▲ +1.05%$7.31 (−22.65%)
Aug 26, 2026
8w ago
6-K
BEARISH ★ 6/10
$9.36 $9.46▼ −1.07%▼ −0.80%$7.31 (+21.90%)
Aug 18, 2026
9w ago
6-K
NEUTRAL ★ 6/10
$9.09 $9.24▲ +1.65%▲ +1.85%$7.31 (−19.58%)
Aug 18, 2026
9w ago
Press Release
MIXED ★ 6/10
$9.09 $9.24▲ +1.65%▲ +1.85%$7.31 (−19.58%)
Jun 2, 2026
20w ago
6-K
NEUTRAL ★ 3/10
$10.04 $9.16▼ −8.76%▼ −5.80%$7.31 (−27.19%)
Jun 1, 2026
21w ago
6-K
BULLISH ★ 7/10
$11.14 $9.79▼ −12.12%▼ −9.37%$7.31 (−34.38%)
Jun 1, 2026
21w ago
Press Release
BULLISH ★ 6/10
$11.14 $9.79▼ −12.12%▼ −9.37%$7.31 (−34.38%)
Showing 10 of 19

US Market Status

Market Closed — Opens in 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh IMTX Intelligence

Analysis is for subscribers only.

Immatics N.V. reported updated Phase 1b clinical data for its PRAME-targeted bispecific IMA402 and Phase 1 data for its PRAME cell therapy IMA203CD8 at the 2026 ESMO annual meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in PRAME-high advanced melanoma patients with a median…

Subscribe for Full Access